Clinical trial
Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer
NCT00265603 · Atlantic Health System, Other · Terminated
Key facts
| NCT number | NCT00265603 |
|---|---|
| Title | Safety Study: Combined Modality Treatment for Non-Small Cell Lung Cancer |
| Official title | Phase 1 Toxicity/Feasibility Study: Combined Modality Treatment With Transimmunization for Non-Small Cell Lung Cancer |
| Lead sponsor | Atlantic Health System, Other |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Procedure |
| Interventions | Extracorporeal Photochemotherapy With Transimmunization |
| Enrollment | 16 |
| Start date | Oct 1, 2004 |
| Primary completion | Apr 1, 2009 |
| Completion | Apr 1, 2009 |
| First posted | Dec 15, 2005 |
| Last update posted | Jan 16, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: